Overview

Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy

Status:
Unknown status
Trial end date:
2016-08-01
Target enrollment:
0
Participant gender:
All
Summary
Comparison of the eradications rates of sequential therapy versus concomitant therapy of treatment of Helicobacter pylori infection in Korea. single center, randomized trial 1. (pantoprazole 40 mg + amoxicillin 1.0g + clarithromycin 500 mg + metronidazole 500 mg) twice for 10 days 2. (pantoprazole 40 mg + amoxicillin 1.0g + clarithromycin 500 mg + metronidazole 500 mg) twice for 14 days 3. (pantoprazole 40 mg + amoxicillin 1.0g) twice for 5 days and subsequent pantoprazole 40mg + clarithromycin 500 mg + metronidazole 500 mg) twice for 5 days 4. (pantoprazole 40 mg + amoxicillin 1.0g) twice for 7 days and subsequent pantoprazole 40mg + clarithromycin 500 mg + metronidazole 500 mg) twice for 7 days 1st endpoint : Helicobacter pylori eradication rates (intention to treatment, per-protocol) 2nd endpoint : adverse event(nausea, vomiting, dizziness, bitter sense) drug compliance
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Incheon St.Mary's Hospital
Treatments:
Amoxicillin
Clarithromycin
Metronidazole
Pantoprazole
Criteria
Inclusion Criteria:

- 20~80 patients

- agreement of informed consent

- H.pylori positive (biopsy, CLO)

- Peptic ulcer disease, mucosa associated lymphoid tissue lymphoma, Post endoscopic
submucosal dissection status due to early gastric cancer

Exclusion Criteria:

- H.pylori eradication history

- severe hepatic, renal, cardiac failure

- pregnancy, participant of other study